Table 3.
Immune checkpoint inhibitors in BRAF-mutant NSCLC.
| Trial | Study Design | ICI | Number of patient/lines | mPFS (s) | mOS (months) | ORR (% |
|---|---|---|---|---|---|---|
| Dudnek | Retrospective | 10 Pembrolizumab 11 Nivolumab 1 Atezolizumab |
12 V600 10 non-V600 |
3.7 4.1 |
NA NA |
25 33 |
| Mazieres | Retrospective | ICI | 43 | 3.1 | 13.6 | 24 |
| Guisier | Retrospective | |||||
| Offin | Retrospective | 10 V600 36 nonV600 |
NA NA |
NA 28.8 |
10 22 |
|
| Hellman | Phase 1/1b | Cobimetinib and Atezolizumab | 28 NSCLC | 29% | 13.2 | 18 |
NA, Not applicable.